Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2024 15:22 ET | Source: AVEO Pharmaceuticals, Inc.

CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned...
March 25, 2024 08:10 ET | Source: AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee

– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer – – Formation of a Scientific Advisory Committee from...
February 06, 2024 08:10 ET | Source: AVEO Pharmaceuticals, Inc.

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist

AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib
July 31, 2023 06:00 ET | Source: Invectys, Inc.

FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma

Houston, TX, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the...
May 03, 2023 03:00 ET | Source: Vaccentis AG

Vaccentis Appoints Dr. Ingrid Rauter as Chief Medical Officer and Head of Research & Development

Zurich, Switzerland, May 3, 2023 - Vaccentis AG, a clinical-stage Swiss biopharmaceutical company developing patient-individualized medicines, today announced the appointment of the experienced life...
September 08, 2022 02:00 ET | Source: Vaccentis AG

Vaccentis strengthens leadership with appointment of Mario Stark as Chief Sales and Marketing Officer

Life science executive with experience in ophthalmology, branding, marketing and financingWill lead sales and marketing of medicines for dry eye and autoimmune diseases Zurich, Switzerland,...
July 12, 2022 02:00 ET | Source: Vaccentis AG

Vaccentis stärkt Management durch Berufung von Martin Munte zum CEO

Pharmamanager mit langjährige Führungserfahrung bei Amgen, AstraZeneca und RocheWeitere Verstärkung des Managements nach Ernennung dreier neuer Mitglieder im Verwaltungsrat Zurich, Schweiz, 12....
July 12, 2022 02:00 ET | Source: Vaccentis AG

Vaccentis appoints Martin Munte as CEO and strengthens Board

Martin Munte has extensive leadership experience at Amgen, AstraZeneca and RocheStrengthening management after appointment of three new Board members Zurich, Switzerland, July 12, 2022 -...
December 22, 2021 08:00 ET | Source: Allarity Therapeutics, Inc.

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs NDA is supported by Allarity’s previously-filed pre-market approval (PMA)...
November 13, 2014 16:06 ET | Source: Daré Bioscience, Inc.

Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results

CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today provided an update on corporate activities during the quarter...

Next Page keyboard_arrow_right